



ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2022 #11

April 1, 2022

INSIDE:

Héma-Québec Moves to Individual Risk-based Donor Screening Criteria for Source Plasma.....	2
RECENT REVIEWS.....	3
RESEARCH IN BRIEF.....	3
INFECTIOUS DISEASES UPDATE.....	4
Photos Available from the 25 th Annual Awards of Excellence.....	5
March ABC Blood Bulletin Now Available.....	5
REGULATORY NEWS.....	6
WORD IN WASHINGTON.....	6
MEMBER NEWS.....	7
CALENDAR.....	7
POSITIONS.....	8

FDA Proposed Rule on Harmonizing Quality System Requirements for Medical Devices with International Standards

The U.S. Food and Drug Administration (FDA) has [proposed](#) a rule that would revise current good manufacturing practice requirements of the Quality System Regulation. This change would “align more closely with the international consensus standard for devices by converging with the quality management system (QMS) requirements used by other regulatory authorities from other jurisdictions.” The agency views the revision as a way to continue its ongoing efforts of further aligning its “regulatory framework with that used by other regulatory authorities to promote consistency in the regulation of devices and provide timelier introduction of safe, effective, high-quality devices for patients.”

Specifically, FDA stated in the proposed rule that “the requirements in the International Organization for Standardization (ISO) 13485 are, when taken in totality, substantially similar to the requirements of 21 CFR Part 820, providing a similar level of assurance in a firm’s quality management system and ability to consistently manufacture devices that are safe and effective and otherwise in compliance with the Federal Food, Drug, and Cosmetic Act.” The agency is proposing that any final rule based on this proposal become effective one year after publication to ensure that manufacturers have adequate time to make changes necessary to comply with the requirements of ISO 13485.17. [Comments](#) on the proposed rule are due by May 24, 2022.

America’s Blood Centers (ABC) is encouraging member blood centers to submit feedback on the proposed rule to ABC, including examples of supplies currently in use and/or being evaluated that would be impacted by this rule. ABC also intends to address this issue with its various committees this month for further discussion and input related to our comment submission. Please contact ABC Chief Medical Officer [Rita Reik, MD](#) comments and questions.

Recently, the FDA also [published](#) a fact sheet on Mitigating and Preventing Medical Device Shortages and Prioritizing Public Health.” The document acknowledges that “[s]hortages in various medical devices critical to public health and safety have remained a problem throughout the pandemic. To help the nation cope with these shortages, the FDA’s Center for Devices and Radiological Health (CDRH) received new statutory authority, under the CARES Act in 2020, to help mitigate and prevent device shortages during or in advance of a public health emergency.” The fact sheet addresses the steps that the agency is taking in creating a news supply chain program

(continued on page 2)

FDA Proposed Rule (continued from page 1)

“to try to help prevent [supply chain issues] before they impact public health” by answering the questions:

- “What did the pandemic teach us about medical device shortages?”
- What is CDRH’s current authority to help address the shortages?
- Won’t the shortages end with the pandemic?
- What will help prevent future shortages?
- What additional authority will CDRH need?
- How do these authorities help industry?”

(Source: MCN 22-035, 3/28/22) 💧

Héma-Québec Moves to Individual Risk-based Donor Screening Criteria for Source Plasma

Héma-Québec, a member of America’s Blood Centers (ABC), recently received authorization from Health Canada, the regulatory body for Canada, to implement individual risk-based donor screening criteria for source plasma donations. According to a [news release](#) announcing the policy shift, “[t]he decision will enable Héma-Québec to move away from the current three-month plasma donor deferral period for all sexually active men who have sex with men, and to instead screen all source plasma donors, regardless of gender or sexuality, for high-risk sexual behavi[o]rs.”

Héma-Québec included data with their submission to Health Canada that “included scientific information and risk modeling data to support the change to donor screening criteria. Source plasma donations undergo testing and other processing, including multiple pathogen inactivation steps, to significantly reduce the risk of contamination with infectious pathogens (e.g., viruses, bacteria, parasites).”

Health Canada is reviewing a similar request from Canada’s other blood provider, Canadian Blood Services, which would “use sexual behavi[o]r screening for all blood and plasma donors instead of the current three-month donor deferral period for men who have sex with men.”

(Source: Health Canada [News Release](#), 3/24/22) 💧

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2022 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America’s Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Rita Reik

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$390

Send subscription queries to

memberservices@americasblood.org

America’s Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.

RECENT REVIEWS

Oncology Patients at Risk of Transfusion-Associated Circulatory Overload. A study in *Laboratory Medicine* focused on the concern that “[t]ransfusion-associated circulatory overload (TACO) is the leading cause of transfusion-related death.” The authors explained that “[o]ncology patients possess unique factors that may increase their risk for TACO.” They conducted a “retrospective [study] [that] audit[ed] all clinical encounters for patients aged 18 years and older who received a blood component transfusion (packed red blood cells [PRBCs], platelets, or thawed plasma) and developed TACO from July 1, 2019 to October 31, 2020...A transfusion medicine physician, using the Centers for Disease Control and Prevention (CDC) guidelines, diagnosed TACO among [the] study population...Additional variables abstracted included comorbidities and cancer treatment modalities, to help identify oncology-specific associations that contribute to TACO.” The researchers noted “[t]here were 1,401 transfusion reactions diagnosed and 93 TACO cases were used for [the] study...The transfusion medicine physician determined the imputability category of TACO diagnoses to be ‘possible’ in 48.4 percent of these clinical encounters, ‘probable’ in 37.6 percent, and ‘definite’ in the remaining 14.0...TACO was more commonly observed in inpatients (n = 85; 91.4 percent), compared with ambulatory patients (n = 8; 8.6 percent)...The primary cancer diagnoses of patients with TACO were hematologic malignancy (70 [75.3 percent]) and solid tumor (23 [24.7 percent]).” The study found that “[t]he type of blood component ordered and administered that resulted in the highest incidence of TACO was PRBCs, leading to 60 TACO cases (64.5 percent)...Those who developed TACO had a mean of 2.5 units of blood products transfused in the 24 hours before the event...Of the 93 patients diagnosed with TACO, 14 patients (15.0 percent) were admitted to the [intensive care unit] because of TACO, and 34 patients (36.6 percent) died within 30 days due to other causes, none of which were deemed to be a result of TACO...A descriptive study of oncology patients who developed TACO revealed characteristics unique to this patient population.” The authors concluded that “[d]eveloping guidelines that apply to oncology patients, in addition to those set forth by the CDC should be considered [and] [a]ddressing gaps in transfusion practices is critical in reducing and mitigating a preventable reaction in an already-vulnerable population.”

Citation: Maldonado, M., Villamin, C.E., Murphy, L.E., Dasgupta, A., Bassett, R.L., Correa Medina, M. [Oncology Patients Who Develop Transfusion- Associated Circulatory Overload: An Observational Study.](#) *Laboratory Medicine.* 2022.

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧

RESEARCH IN BRIEF

Data on COVID-19 Convalescent Plasma in the Outpatient-setting. Researchers [published](#) data this week in the *New England Journal of Medicine* from a multicenter, double-blind, randomized, controlled trial that assessed the “safety and efficacy of COVID-19 convalescent plasma (CCP) as compared with control plasma, in symptomatic adults (≥ 18 years of age) who had tested positive for severe acute respiratory syndrome coronavirus 2, regardless of their risk factors for disease progression or vaccination status.” According to a [news release](#) announcing the study’s findings, their research “showed that high-titer (antibody-rich) CCP — when administered to COVID-19 outpatients within nine days after testing positive — reduced the need for hospitalization for more than half of the study’s predominantly unvaccinated outpatients. The U.S. Food and Drug Administration (FDA) currently authorizes this plasma as a treatment option for outpatients with immunocompromising diseases or receiving immunocompromising medications, and for all patients hospitalized with early-stage COVID-19.” The trial took place at 23 sites throughout the U.S. and participants had tested positive for SARS-CoV-2 and were within eight days of the onset of symptoms for COVID-19. Individuals who had previously been hospitalized due to COVID-19, or received monoclonal antibodies prior to enrollment, or had experienced prior reactions to transfusions of blood products, or planned hospitalization within 24 hours after enrollment were excluded. The study included 1,181

continued on page 4)

RESEARCH IN BRIEF (continued from page 3)

participants (592 received convalescent plasma and 589 received control plasma). The researchers stated that 333 units of CCP from unique donors were transfused into 592 participants. “The results suggest that point-estimate outcomes were better in participants who received a transfusion within 5 days after the onset of symptoms than in those who received a transfusion later. Most participants who were hospitalized were unvaccinated (53 of 54 participants).” The researchers concluded that “[t]he results of our blinded, multisite trial are consistent with those of previous trials of antibody-based therapies. These trials have shown that effectiveness is associated with early administration of sufficient amounts of pathogen-specific antibodies to mediate an antiviral effect...Our trial has important public health implications, especially in resource-constrained areas with imbalances in vaccine distribution. CCP can be considered for initial use in patients with COVID-19 and for use in future pandemics while monoclonal therapies and vaccines are being developed...Even in the current pandemic, the continued propagation of SARS-CoV-2 variants with evolving resistance to currently available monoclonal antibodies indicates the potential usefulness of developing capacity for the availability and distribution of CCP, especially because locally sourced, recently obtained plasma should include antibodies to circulating strains.”

Citation: Sullivan, D., Gebo, K., Shoham, S. *et al.* Early Outpatient Treatment for Covid-19 with Convalescent Plasma. *The New England Journal of Medicine*. 2022. Doi: [10.1056/NEJMoa2119657](https://doi.org/10.1056/NEJMoa2119657). ♦

INFECTIOUS DISEASES UPDATE**HEPATITIS B VIRUS**

Nature has [published](#) a supplement exploring hepatitis B. The supplement includes a series of 14 features and commentaries that address the steps that have been taken worldwide to control and treat hepatitis B in addition to raising awareness of the ongoing challenges that low-resource communities face globally in stopping its spread, highlighting advances in research towards a potential cure.

(Source: *Nature Outlook* [Supplement](#), 3/30/22) ♦



Technical & Quality Workshop
April 4-7, 2022
Louisville, KY

Featuring Inventory Management,
Component Manufacturing, Laboratory
Operations, and Quality Systems.

America's Blood Centers
It's About Life.



MAY 10-12, 2022 • PHOENIX, AZ

ANNUAL CONFERENCE

ADRP
An International Division of ABC

RECRUITMENT • COLLECTIONS • MARKETING • COMMUNICATIONS • PUBLIC AWARENESS



America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

Photos Available from the 25th Annual Awards of Excellence

America's Blood Centers recently honored the recipients of the 25th Annual *Awards of Excellence*, during the 60th ABC Annual Meeting. These awards allow ABC to recognize individuals and organizations that have made outstanding contributions in promoting blood donation and improving transfusion medicine. All photos from the General Session, awards ceremony, and the Casino Night event celebrating ABC turning 60 are available [here](#).

March ABC Blood Bulletin Now Available

ABC's Scientific, Medical, and Technical (SMT) Publications Committee has published the March 2022 Issue of the [Blood Bulletin](#), titled "Blood Shortages — How Hospitals Can Help." The article was written by Debra Smith, MD, PhD, Associate Medical Director at Oklahoma Blood Institute; Nanci Fredrich, RN, BSN, MM, Transfusion Safety & Blood Management Officer at Versiti; Kirsten Alcorn, MD, Co-Chief Medical Officer at Bloodworks Northwest; Samantha Ngamsuntikul, MD, Associate Medical Director at South Texas Blood & Tissue Center, a subsidiary of BioBridge Global; Nancy Van Buren, MD, Medical Director at Innovative Blood Resources, a division of New York Blood Center. Contributors included Louis Katz, MD, Chief Medical Officer at ImpactLife; Richard Gammon, MD, Medical Director at OneBlood; Claudia Cohn, MD, PhD, Professor of Laboratory Medicine and Pathology at the University of Minnesota. The [Blood Bulletin](#) is reviewed and edited by ABC's SMT Publications Committee. ABC publishes the *Blood Bulletin* for use by member blood centers in their educational programs as a value-added service for hospital customers. Please contact [Member Services](#) for trouble accessing the publication.

Please note: The MS Word version may not display properly for users with older versions of MS Word. For those individuals, we recommend viewing and using the PDF version of this publication instead.

(Source: MCN 22-031, 3/4/22) 💧

NEW on CollABORate

COLLABORATE

SHARE STRATEGIC ADVICE | SOLVE CHALLENGES | DEVELOP NEW APPROACHES

Recent discussion topics on the ABC [CollABORate](#) Online Member Community include:

- [Donor Identification/DIN Verification](#) (COLLECTIONS & DONOR SERVICES)
- [PPE for Collection Staff](#) (COLLECTIONS & DONOR SERVICES)
- [Investigating Possible Duplicate Donors](#) (COLLECTIONS & DONOR SERVICES)
- [Pediatric Out-of-Group Platelet Transfusion/Donor Notification HLA Antibodies](#) (MEDICAL ISSUES)

ABC members are encouraged to [login](#) and join the conversations today!

REGULATORY NEWS

On March 22nd the U.S. Food and Drug Administration (FDA) [published](#) the final guidance document titled, “An Acceptable Circular of Information for the Use of Human Blood and Blood Components.” The guidance supersedes December 2017 guidance and states “FDA [and] the Center for Biologics Evaluation and Research are recognizing as acceptable for use by you, manufacturers of blood and blood components intended for transfusion, the document entitled ‘Circular of Information for the Use of Human Blood and Blood Components,’ dated December 2021.” The changes to the *Circular of Information* were previously [covered](#) in the *ABC Newsletter* on December 17, 2021.

(Source: FDA [Guidance](#) 3/22/22) ◆

BRIEFLY NOTED

The Centers for Disease Control and Prevention (CDC) has launched the National Blood Collection and Utilization Survey (NBCUS) with a closing date of May 6th. NBCUS is conducted every two years and provides invaluable data on the amount of blood collected by U.S. blood centers and used by U.S. hospitals. Nearly all members of America’s Blood Centers participated in the previous NBCUS, which was vital to the success of the survey. Blood centers are highly encouraged to submit responses prior to the deadline. All participants should have already received an e-mail from CDC with a secure web-link to complete the survey. If you did not receive the link, or if you have any questions, please contact [Sridhar V. Basavaraju MD, FACEP](#) at CDC’s Office of Blood, Organ, and Other Tissue Safety.

(CDC Announcement, 3/26/22)

Horizon Technology Finance Corporation [announced](#) “it closed a \$15 million venture loan facility to Secure Transfusion Services, Inc. (‘STS’), of which Horizon funded \$5 million of the initial \$10 million draw, and a private investment vehicle managed by Horizon Technology Finance Management LLC, Horizon’s adviser, funded \$5 million.” According to the news release, “STS operates commercial blood collection centers that source and distribute vital, in-demand blood components, such as platelets, to hospitals,” including the operation of Trusting Heart Blood Centers in Minnesota and North Carolina that compensate platelet donors financially.

(Source: Horizons Technology Finance Corporation [News Release](#), 3/17/22) ◆

WORD IN WASHINGTON

The Office of the Actuary within the Centers for Medicare and Medicaid Services (CMS) recently published data on national health expenditures and projections for 2021-2030. According to a [news release](#) from the agency, “despite the increased demand for patient care in 2021, the growth in national health spending is estimated to have slowed to 4.2 percent, from 9.7 percent in 2020, as supplemental funding for public health activity and other federal programs, specifically those associated with the COVID-19 pandemic, declined significantly...The report finds that annual growth in national health spending is expected to average 5.1 percent over 2021-2030, and to reach nearly \$6.8 trillion by 2030. Growth in the nation’s Gross Domestic Product (GDP) is also projected to be 5.1 percent annually over the same period. As a result of the comparable projected rates of growth, the health share of GDP is expected to be 19.6 percent in 2030, nearly the same as the 2020 share of 19.7 percent.”

(Source: CMS [News Release](#), 3/28/22) ◆



MEMBER NEWS

[The Blood Emergency Readiness Corps](#) (BERC) recently announced the [addition](#) of **Community Blood Center of the Ozarks** (CBCO) . “We are proud to join other independent blood centers across the country on the BERC team,” said Anthony Roberts, CBCO Executive Director in a news release. “Our mission as the region’s exclusive blood supplier does not change. What will change is our ability to better handle events in our area that require many transfusions within a short period of time. Our collaboration with BERC helps to provide that assurance.” CBCO Senior Director of Donor Recruitment and Marketing Kenda Burnham added in the news release, “CBCO has a mission to provide blood locally, but I know that in times of national crisis our donors are eager to help those in need wherever they may be. Our involvement in BERC creates that opportunity. If local donors want to help, they can simply continue to give blood on a regular basis. Ask others to do the same. That way we will be ready if or when tragedy strikes.”

(BERC [News Release](#), 3/22/22) 💧

CALENDAR

***Note to subscribers:** Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)*

2022

April 4-7. **ABC Technical and Quality Workshop, Louisville, Ky.** Registration is [open](#). More information available [here](#).

April 12-13. **17th Annual FDA and the Changing Paradigm for HCT/P Regulation, Cambridge Md.** Registration is [open](#). More information available [here](#).

May 10-12. **2022 ADRP Conference, Phoenix, Ariz.** Registration is [open](#). More information available [here](#).

June 4-8. **37th Annual International Congress of ISBT, Kuala Lumpur, Malaysia.** More information available [here](#).

Aug. 2-4. **ABC Summer Summit and Medical Directors Workshop, Minneapolis, Minn.** More information coming [soon](#).

Sept. 21-22. **28th IPFA/ Paul-Ehrlich-Institut[e] (PEI) International Workshop, Porto, Portugal.** More information coming soon.

Oct. 1-4. **Association for the Advancement of Blood & Biotherapies Annual Meeting, Orlando, Fla.** More information available [here](#).

2023

Mar. 6-8. **ABC Annual Meeting, Washington, D.C.** More information coming soon.

May 9-11. **2023 ADRP Conference.** More information coming soon. 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for *ABC Newsletter* subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Implementation Specialist (BBCS). Blood Bank Computer Systems (BBCS) is hiring for a remote implementation Specialist. Reporting to the Client Services Manager, this position will be responsible for establishing, maintaining, and managing client implementation work plans, assisting with the installation/upgrade of BBCS applications at client facilities, assisting the client in meeting the projected Go Live dates, new client management training, on-site consultations, and training. Requirements: Bachelor's degree, three plus years of successful project management/implementation experience, tradeshow participation, product and industry knowledge, experience with healthcare and/or IT implementation. To apply visit our BBCS careers website at: <https://www.bbcinc.com/about/bbcs/careers/>

Outside Sales Representative/Event Planner (Ardmore, Oklahoma). Outside sales representatives must develop new partnerships with targeted decision makers in community organizations, educational & religious institutions, and businesses to gain support in meeting the needs for volunteer blood donors. Responsibilities include organizing and promoting blood donation events; assessing, developing, and implementing strategic/tactical plans to achieve recruitment objective/goals. She/he is expected to develop a customer-focused culture that will result in successful community partnerships and donation awareness. Identify opportunities for growth within current group base, and facilitate a plan to achieve growth percentage for total unit collection within territory. Book recurring blood drives for the following year. Develop and maintain relationships with key accounts. Give presentations in order to promote blood collection. Identify and provide feedback on issues regarding customer needs/requirements, customer issues/concerns and satisfaction, competitor activities/strategies, etc. Interact effectively and professionally with team members and all internal/external contacts. Qualifications: Associate/bachelor's degree preferred, one to three years sales related experience, public speaking/presentation experience preferred, excellent communication skills, and valid driver's license with access to vehicle. Salary Range: Competitive salary, commission plan, and excellent benefits package including health, dental, vision, and life insurance, 401(k), paid time off, and holiday pay. **How to apply:** <http://obi.org/careers/>

Territory Sales Consultant (Fort Smith, Arkansas). Outside sales representatives must develop new partnerships with targeted decision makers in community organizations, educational and religious institutions, and businesses to gain support in meeting the needs for volunteer blood donors. Responsibilities include organizing and promoting blood donation events; assessing, developing, and implementing strategic/tactical plans to achieve recruitment objective/goals. She/he is expected to develop a customer-focused culture that will result in

successful community partnerships and donation awareness. Identify opportunities for growth within current group base and facilitate a plan to achieve growth percentage for total unit collection within territory. Book recurring blood drives for the following year. Develop and maintain relationships with key accounts. Give presentations to promote blood collection. Identify and provide feedback on issues regarding customer needs/requirements, customer issues/concerns and satisfaction, competitor activities/strategies, etc. Interact effectively and professionally with team members and all internal/external contacts. Qualifications: Associate/bachelor's degree preferred, one to three years sales related experience, public speaking/presentation experience preferred, excellent communication skills, and valid driver's license with access to vehicle. Salary Range: Competitive salary, commission plan, and excellent benefits package including health, dental, vision, and life insurance, 401(k), paid time off, and holiday pay. **How to apply:** <http://arkbi.org/careers/>.

Director, Information Technology. The National Blood Testing Cooperative (NBTC) lab in Stone Mountain, GA is seeking and interviewing for the full-time position of Director of Information Technologies. Essential function of this position is to be accountable for overall operations of the IT department, reporting to the VP of Finance. Will work to develop short- and long-term objectives with the primary responsibility of establishing and achieving corporate IT goals and security. Analyzes the needs of the organization and determines ways to meet the business objectives by modifying existing or developing new information processing systems. Bachelor's degree in computer science or related field required. The applicant for this position must have five or more years of experience working with a concentration on management of information technology and must have five or more years of job-related experience. NBTC pays a competitive starting wage and full benefits package including paid holidays, health, dental and life insurance on date of hire, paid time off after six months and an employer contributed retirement plan. If you meet the above qualifications and would like to apply, please email your resume to mharper@nationalbloodcollaborative.org. **EOE/AEE**

Medical Technologist - IRL Lab. LifeSouth Community Blood Centers is currently seeking a skilled individual for a **Medical Technologist** position in our Immunohematology Reference Laboratory (IRL) in **Gainesville, FL**. This position is responsible for performing and interpreting clinical laboratory tests that require the exercise of independent judgment. This is a full-time position. Starting salary range is \$27.00 - \$32.40 an hour. Shift differential may apply. LifeSouth offers a competitive benefits package and great career development opportunities. Background check and drug

(continued on page 9)

POSITIONS (continued from page 8)

test required. Equal Opportunity/Affirmative Action Employer/DFWP/Tobacco Free. **Applicants should apply here:** <https://lifesouth.csod.com/ux/ats/career-site/5/home/requisition/2697?c=lifesouth>

Medical Technologist - Special Testing. LifeSouth Community Blood Centers is currently seeking a skilled individual for a **Medical Technologist** position in our Special Testing Laboratory in **Gainesville, FL**. This position is responsible for performing and interpreting clinical laboratory tests that require the exercise of independent judgment. This lab covers diverse testing methodologies in the areas of flow cytometry, molecular biology, coagulation, hematology, cellular therapies, histocompatibility, and serology. This is a full-time position. Starting salary range is \$27.00 - \$32.40 an hour. Shift differential may apply. LifeSouth offers a competitive benefits package and great career development opportunities. Background check and drug test required. Equal Opportunity/Affirmative Action Employer/DFWP/Tobacco Free. **Applicants should apply here:** <https://lifesouth.csod.com/ux/ats/career-site/5/home/requisition/2698?c=lifesouth>

Vice President of Business Intelligence. The National Blood Collaborative (NBC) is now interviewing for the full-time position Vice President of Business Intelligence. This position reports directly to the Board of Directors and relocation is not required. NBC is owned by eight independent blood centers and was created in 2012 focusing on unique revenue opportunities including resource sharing and cellular therapy. <https://www.nationalbloodcollaborative.org/>. This position is responsible for directing and controlling the planning, development and implementation of sales strategies, marketing communications and public relations functions for the Collaborative. Experience obtaining new customers (blood products and related cellular materials) is required. Position will also assist individual members in obtaining new business when requested and will oversee development and implementation of support materials. This position requires a bachelor's degree – master's preferred. National Blood Collaborative (NBC) pays a competitive starting wage and full benefits package including paid holidays, health, dental and life insurance, paid time off and an employer contributed retirement plan. If you meet the above qualifications and would like to work for a company that impacts our industry, please email your resume to egolemi@thebloodcenter.org. Only resumes with salary requirements will be considered. Resumes submitted are held in strict confidence. EOE/AAE

Medical Laboratory Technologist (MLT). The Blood Bank of Alaska (BBAK) is seeking a MLT to join our team in Anchorage, Alaska. This position will be responsible for providing broad support and technical assistance in the product QC laboratory working under the direction

of the Laboratory Services Director. Performing necessary duties for day-to-day operations in the product QC laboratory. Assisting management team with compliance related activities as qualified and other support duties as assigned. Working as a team player with other members of the product QC laboratory. Demonstrating ownership and accountability for product QC laboratory activities. Minimum: Bachelor's degree in biological science or associate's degree with MLT certification. Previous work experience in a blood bank/donor center laboratory preferred. MT/CLS or MLT or equivalent certification preferred. We are committed to providing our employees with the support they need. At BBAK we offer an attractive benefit package that includes: Medical, Dental, Vision, Life Insurance, Health Savings Plan, Paid Time Off, 401 K with matching and short Term & Long-Term Disability coverage. View the complete job description at www.BloodBankofAlaska.org. If interested, please contact or HR Director for additional information at MCannon@bbak.org.

Registered Nurse. LifeSouth Community Blood Centers is currently seeking experienced professionals to join our team as **Registered Nurses in Gainesville, FL, and Jacksonville, FL**. This position is responsible for traveling to hospitals to perform therapeutic apheresis procedures. Nurses will only care for one patient at a time and will work alongside hospital nurses and physicians to complete procedures. Nurses will also spend time at the LifeSouth office to coordinate upcoming apheresis procedures and organize necessary documentation. Training: Don't let a lack of apheresis experience stop you from applying! No previous apheresis experience is required. If hired, you will be given sufficient on-the-job training to learn the specialized skills this position requires. Training for this position will be conducted during regular business hours. This is a full-time position. Starting salary range is \$67,500 - \$74,250 annually plus travel and on-call bonus. Background check and drug test required. Equal Opportunity/Affirmative Action Employer/DFWP/Tobacco Free. Applicants should apply [here](#) for the Gainesville, FL location. Applicants should apply [here](#) for the Jacksonville, FL location.

Laboratory Director. We have a wonderful opening for a Laboratory Director position within the Cell Therapy Program at Bloodworks Northwest. The incumbent in this role will provide leadership, management, oversight, and subject matter expertise of all operational, technical, and scientific aspects of the Cell Therapy Program, including Cord Blood Services (CBS), Cell Processing Laboratory (CPL), and Advanced Cell Processing (ACP). This role ensures that all laboratory and technical policies, processes, and procedures as well as quality programs meet the highest organizational and departmental expectations, as well as being compliant with applicable laws, regulations, and standards (for example,

(continued on page 10)



POSITIONS (continued from page 9)

FDA, CLIA, AABB, FACT, CAP, NMDP and others). The incumbent will provide direction for securing new business opportunities, maximizing revenue, and maintaining and supporting the customer base of the Cell Therapy Program. This role will require minimal supervision but works in close collaboration with departmental leadership/management team. To apply and review full posting, click [here](#).

Specialist in Blood Banking Students. LifeSouth Community Blood Centers, Inc. is accepting applications for our accredited online SBB training program, class of 2022-2023. Please visit <https://www.lifesouth.org/specialist-in-blood-banking-certificate-program/> for eligibility, other application details, and application forms. The application period ends on April 15th, 2022. Starting date for the 12-month program is June 13, 2023. If interested, please contact Bill Martinez for additional information, gamartinez@lifesouth.org. ♦